Ambler class |
Protein name |
PDB code |
Resolution (Å) |
Release date |
UniProt code |
PubMed ID |
DOI |
PDB |
Mutations |
Ligands |
Space group |
Unit cell parameters |
Z value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ||||||||
B3 | L1-44 | 6U0Y | 1.70 | 2019-09-11 | B2FTM1 | pdb | EDO ZN | P 1 21 1 | 68.033 97.229 91.725 ♦ 90.00 105.55 90.00 | 8 | |||
B3 | L1-44 | 6U0Z | 1.65 | 2019-09-11 | B2FTM1 | pdb | #PNK PEG SO4 SUC ZN | P 64 2 2 | 104.759 104.759 98.434 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 6U10 | 1.40 | 2019-09-11 | B2FTM1 | pdb | #X8Z EDO FMT ZN | P 64 2 2 | 104.537 104.537 98.723 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 6U13 | 1.52 | 2019-09-11 | B2FTM1 | pdb | #MX1 EDO ZN | P 64 2 2 | 103.918 103.918 98.929 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 6U2Y | 1.50 | 2019-09-04 | B2FTM1 | pdb | #MX1 EDO NI | P 64 2 2 | 104.132 104.132 98.927 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 6U2Z | 2.38 | 2019-09-04 | B2FTM1 | pdb | #3P7 CU EDO | P 64 2 2 | 104.234 104.234 98.793 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 6UA1 | 1.80 | 2019-09-18 | B2FTM1 | pdb | EDO | P 64 2 2 | 104.467 104.467 99.035 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 6UAC | 1.60 | 2019-09-25 | B2FTM1 | pdb | #MX1 CD EDO | P 64 2 2 | 104.339 104.339 98.975 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 6UAF | 1.90 | 2019-09-18 | B2FTM1 | pdb | #HIW ZN | P 64 2 2 | 104.835 104.835 98.627 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 6UAH | 1.98 | 2019-09-18 | B2FTM1 | pdb | #LMP EDO PGE ZN | P 64 2 2 | 104.410 104.410 98.849 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 7L52 | 1.85 | 2020-12-30 | B2FTM1 | pdb | ZN | P 64 2 2 | 105.668 105.668 99.332 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 7L91 | 2.20 | 2022-02-09 | B2FTM1 | pdb | #XQP ZN | P 64 2 2 | 105.853 105.853 99.100 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 7UHH | 2.20 | 2022-04-13 | B2FTM1 | pdb | #MX0 ZN | P 64 2 2 | 105.853 105.853 99.100 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 7UHI | 2.20 | 2022-04-13 | B2FTM1 | pdb | #MX0 ZN | P 64 2 2 | 105.853 105.853 99.100 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 7UHJ | 2.20 | 2022-04-13 | B2FTM1 | pdb | #MX0 ZN | P 64 2 2 | 105.853 105.853 99.100 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 7UHK | 2.20 | 2022-04-13 | B2FTM1 | pdb | #MX0 ZN | P 64 2 2 | 105.853 105.853 99.100 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 7UHL | 2.20 | 2022-04-13 | B2FTM1 | pdb | #MX0 ZN | P 64 2 2 | 105.853 105.853 99.100 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 7UHM | 2.70 | 2022-06-29 | B2FTM1 | pdb | #XQP ZN | P 64 2 2 | 105.853 105.853 99.100 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 7UHN | 2.20 | 2022-04-13 | B2FTM1 | pdb | #XQP ZN | P 64 2 2 | 105.853 105.853 99.100 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 7UHO | 2.20 | 2022-07-13 | B2FTM1 | pdb | #XQP ZN | P 64 2 2 | 105.853 105.853 99.100 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 7UHP | 2.60 | 2022-04-13 | B2FTM1 | pdb | #XQP ZN | P 64 2 2 | 105.853 105.853 99.100 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 7UHQ | 2.20 | 2022-04-13 | B2FTM1 | pdb | #XQP ZN | P 64 2 2 | 105.853 105.853 99.100 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 7UHR | 2.20 | 2022-04-13 | B2FTM1 | pdb | ZN | P 64 2 2 | 105.853 105.853 99.100 ♦ 90.00 90.00 120.00 | 12 | |||
B3 | L1-44 | 7UHS | 2.20 | 2022-04-13 | B2FTM1 | pdb | P 64 2 2 | 105.951 105.951 99.886 ♦ 90.00 90.00 120.00 | 12 | ||||
B3 | L1-44 | 7UHT | 2.20 | 2022-04-13 | B2FTM1 | pdb | ZN | P 64 2 2 | 106.094 106.094 99.772 ♦ 90.00 90.00 120.00 | 12 |
Statistics (number of structures): Overall (1663); class A (626); subclass B1 (403); subclass B2 (16); subclass B3 (104); class C (246); class D (268).
Last updated: November 20, 2024.
If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.
The development of the BLDB database was funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).
Contact: contact@bldb.eu